Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder – a naturalistic mirror image study

References

• Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387(10027):1561–1572.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
   PubMed Web of Science ®Google Scholar
• Keck PE Jr., McElroy SL, Havens JR, et al. Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Compr Psychiatry. 2003;44(4):263–269.
   PubMed Web of Science ®Google Scholar
• Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
   PubMed Web of Science ®Google Scholar
• Lopez-Jaramillo C, Lopera-Vasquez J, Gallo A, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12(5):557–567.
   PubMed Web of Science ®Google Scholar
• Winkelman NW. Chlorpromazine in the treatment of neuropsychiatric disorders. J Am Med Assoc. 1954;155(1):18–21.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Barbui C, Salanti G, et al. Comparative effectiveness and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306–1315.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Tohen M, Banov MD, et al. Is clozapine a mood stabilizer? J Clin Psychiatry. 1995;56(3):108–112.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–117.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553.
   PubMed Web of Science ®Google Scholar
• Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014;349(255):g5673.
   PubMedGoogle Scholar
• Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11(3):227–240.
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164–172.
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8(3):232–241.
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry. 2002;159(11):1927–1929.
   PubMed Web of Science ®Google Scholar
• Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv. 2011;62(9):1032–1040.
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS. Medication adherence and the use of long-acting antipsychotics in bipolar disorder. J Psychiatr Pract. 2007;13(2):79–85.
   PubMedGoogle Scholar
• Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol. 1995;9(Suppl. 5):17–20.
   PubMed Web of Science ®Google Scholar
• Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001;179:300–307.
   PubMed Web of Science ®Google Scholar
• Patel MX, David A. Why aren’t depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treatment. 2005;11(3):203–211.
   Google Scholar
• Gray R, Spilling R, Burgess D, et al. Antipsychotic long-acting injections in clinical practice: medication management and patient choice. Br J Psychiatry. 2009;195(S52):s51–s56.
   Google Scholar
• Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand. 2007;116(s434):3–16.
   Google Scholar
• Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand. 1981;64(3):226–237.
   PubMed Web of Science ®Google Scholar
• White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol. 1993;8(2):119–122.
   PubMed Web of Science ®Google Scholar
• Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry. 1994;165(6):827–829.
   PubMedGoogle Scholar
• Naylor GJ, Scott CR. Depot injections for affective disorders. Br J Psychiatry. 1980;136:105.
   PubMed Web of Science ®Google Scholar
• Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol. 1986;1(Suppl. 1):53–62.
   PubMedGoogle Scholar
• Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry. 1986;148:723–725.
   PubMed Web of Science ®Google Scholar
• Gigande AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012;26(5):403–420.
   PubMed Web of Science ®Google Scholar
• Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006;67(1):107–113.
   PubMed Web of Science ®Google Scholar
• Chou YH, Chu PC, Wu SW, et al. A systemic review and experts' consensus for long-acting injectable antipsychotics in bipolar disorder. Clin Psychopharmacol Neurosci. 2015;13(2):121–128.
   PubMed Web of Science ®Google Scholar
• Samalin L, Charpeaud T, Lorabi O, et al. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. Patient Prefer Adherence. 2010;4:325–334.
   PubMed Web of Science ®Google Scholar
• Keramatian K, Chakrabarty T, Yatham LN. Long-acting injectable second-generation/atypical antipsychotics for the management of bipolar disorder: a systematic review. CNS Drugs. 2019;33(5):431–456.
   PubMed Web of Science ®Google Scholar
• Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453–473.
   PubMed Web of Science ®Google Scholar
• Özalp E, Karslıoğlu EH. Treatment resistant bipolar disorder. Psikiyatride Güncel Yaklaşımlar Curr Approach Psychiatry. 2015;7(4):401–418.
   Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to asses routine functioning. Acta Psychiatr Scand. 2000;101(4):323–329.
   PubMed Web of Science ®Google Scholar
• Aydemir Ö, Üçok A, Esen-Danacı A, et al. Validation of Turkish version of Personal and Social Performance Scale (PSP). Klinik Psikofarmakol BüLteni. 2009;19:93–100.
   Google Scholar
• Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
   PubMed Web of Science ®Google Scholar
• Karadağ F, Oral ET, Yalçın FA, et al. Reliability and validity of Turkish translation of Young Mania Rating Scale. Turk Psikiyatri Derg. 2002;13:107–104.
   PubMedGoogle Scholar
• Beck AT, Steer RA. Internal consistencies of the original and revised BDI. J Clin Psychol. 1984;40(6):1365–1367.
   PubMed Web of Science ®Google Scholar
• Hisli N. Beck Depresyon Envanterinin üniversite öğrencileri için geçerliği, güvenirliği. Psikoloji Dergisi. 1989;7(23):3–13.
   Google Scholar
• Thomas DM, Clark N, Turner D, et al. Best (but oft-forgotten) practices: identifying and accounting for regression to the mean in nutrition and obesity research. Am J Clin Nutr. 2020;111(2):256–265.
   PubMed Web of Science ®Google Scholar
• Meyer JM. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr. 2013;18(s1):55–67.
   Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–288.
   PubMed Web of Science ®Google Scholar
• Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Rev Neurother. 2017;17(10):1029–1043.
   PubMed Web of Science ®Google Scholar
• Vieta E, Nieto E, Autet A, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008;9(3):219–224.
   PubMed Web of Science ®Google Scholar
• Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol. 2008;23(2):88–94.
   PubMed Web of Science ®Google Scholar
• Han C, Lee M, Pae C, et al. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1219–1223.
   PubMed Web of Science ®Google Scholar
• Bräunig P, Sacchetti E, Medori R. Risperidone long-acting injectable for maintenance therapy in bipolar disorder: an open-label pilot study. Int J Psychiatry Clin Pract. 2008;12(1):74–77.
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry. 2010;68(2):156–162.
   PubMed Web of Science ®Google Scholar
• Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22(11):825–835.
   PubMed Web of Science ®Google Scholar
• Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord. 2009;11(8):827–839.
   PubMed Web of Science ®Google Scholar
• Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol. 2006;26(5):530–531.
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Chuang P-Y, Wu C-S, et al. Bipolar patients treated with long-acting injectable risperidone in Taiwan: a 1-year mirror-image study using a national claims data-base. J Affect Disord. 2017;218:327–334.
   PubMed Web of Science ®Google Scholar
• Macfadden W, Adler CM, Turkoz I, et al. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry. 2011;11(1):171.
   PubMedGoogle Scholar
• Lähteenvuo M, Tanskanen A, Taipale H, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish Nationwide Cohort of patients with bipolar disorder. JAMA Psychiatry. 2018;75(4):347–355.
   PubMed Web of Science ®Google Scholar
• Torres-Llenza V, Lakshmin P, Lieberman DZ. Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. Neuropsychiatr Dis Treat. 2018;14:285–292.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Curr Med Res Opin. 2018;34(1):41–47.
   PubMed Web of Science ®Google Scholar